ECO Animal Health Group plc
(''ECO" or "the Group")
(AIM: EAH)
Animal Health, Nutrition & Technology Innovation
ECO Animal Health Group plc ("ECO" or "the Group"), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, is pleased to announce that it will be participating at the Animal Health, Nutrition and Technology Innovation summit and leading the round table discussion on swine disease management.
Animal Health, Nutrition and Technology Innovation Europe is the sector's premier innovation summit, showcasing the emerging companies and connecting them with investors and strategic partners. The summit engages all key participants in the value chain so it can address the full scope of how animal health impacts pet owners, veterinarians, and farmers today.
Please find further information on the event at https://kisacoresearch.com/events/animal-health-europe-2023
Contacts:
| ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO)
|
|
| IFC Advisory Graham Herring Zach Cohen
| 020 3934 6630
|
| Singer Capital Markets (Nominated Adviser & Joint Broker) Phil Davies George Tzimas
| 020 7496 3000 |
| Investec (Joint Broker) Gary Clarence Daniel Adams Carlo Spingardi
| 020 7597 5970 |
| Equity Development Hannah Crowe Matt Evans | 020 7065 2692 |
About ECO Animal Health
ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
